|
Sub-category:
Prognostic Factors
Category:
Tumor Biology and Human Genetics
Meeting:
2009 ASCO Annual Meeting
Session Type and Session Title:
Poster Discussion, Tumor Biology and Human Genetics
Abstract No:
11020
Citation:
J Clin Oncol 27:15s, 2009 (suppl; abstr 11020)
Author(s):
P. Y. Rosenblatt, M. J. Edelman, R. H. Christenson, L. Hodgson, X. Wang, R. Kratzke, E. Vokes; University of Maryland, Baltimore, MD; University of Maryland Greenebaum Cancer Center, Baltimore, MD; Duke University, Durham, NC; University of Minnesota, Minneapolis, MN; University of Chicago, Chicago, IL
Abstract:
Background: Cytokeratin 19 and its soluble fragment CYFRA have been studied as markers that may correlate with response to therapy and survival in NSCLC. As part of CALGB 30203, a randomized trial of carboplatin/gemcitabine with eicosanoid modulators (celecoxib, zileuton or both) in advanced NSCLC (Edelman JCO 2008), serum CYFRA levels were obtained prior to and during treatment. The objective of this study was to evaluate the possible correlation of CYFRA as a predictive and prognostic marker and to confirm a previous finding that a 27% reduction in CYFRA after one cycle (21 days) of treatment correlated with a longer survival (Vollmer Clin Ca Res, 2003). Methods: Paired specimens were available from 88 patients. CYFRA was measured at baseline and after cycles 1 and 2 using an electrochemoluminescent assay (Roche Diagnostics) on the ElecSys 2010 system as previously described. Using logarithm of the initial concentration and logarithm of the difference in concentrations, we analyzed these in relation to overall survival (OS) and failure free survival (FFS). Results: 1. Lower baseline CYFRA levels were associated with both longer overall survival and failure free survival (p = <0.0001 and p=0.0045). 2. Larger reductions in CYFRA levels correlated to longer overall survival and failure-free survival (p=0.0254 and p=0.0298). 3.We failed to replicate that a drop of >27% in CYFRA levels had statistical significance in overall or failure free survival (p=0.6489 and p=0.9636). Conclusions: CYFRA and change in CYFRA appear to be reliable markers in predicting the response to chemotherapy for nonsmall cell lung cancer; however, a precise threshold to mark response has yet to be determined.
Abstract Disclosures
Faculty and Discussant Disclosures
Annual Meeting Planning Committee Disclosures
2009 Annual Meeting Proceedings Part I Errata
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy
and are designated with a caret symbol (^) here and in the print version.
 Associated Presentation(s):
Other Abstracts in this Sub-Category:
Abstracts by P. Y. Rosenblatt:
Presentations by P. Y. Rosenblatt:
Educational Book Manuscripts by P. Y. Rosenblatt:
|
